Russian registry for people with very high triglycerides
Official title: Russian Extreme Hypertriglyceridemia Registry (REGGI)
Run by Russian Cardiology Research and Production Center · NCT07508930 · Data updated 2026-11-12
This registry collects health and genetic information from people in Russia who have very high triglycerides (≥10 mmol/L) to see what their causes, care, and outcomes look like.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Russian Cardiology Research and Production Center Academic / other |
| Locations | 6 sites (Astrakhan and 5 other locations) |
| Status | Recruiting |
| Started | November 20, 2025 |
| Main results expected | December 2045 |
| Study ends | December 2045 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07508930 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Anyone in Russia of any age with confirmed extreme hypertriglyceridemia (triglycerides ≥10 mmol/L on at least two separate tests) who can give informed consent is eligible.
✕Probably not a fit
People whose very high triglycerides are clearly due to ongoing alcohol abuse or uncontrolled secondary conditions and who are not confirmed to have persistent extreme levels after treating the underlying cause may not benefit from the registry findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Russian Extreme Hypertriglyceridemia Registry is a prospective, multicenter observational effort enrolling patients with triglyceride levels ≥10 mmol/L confirmed on at least two occasions. It records demographic, clinical, laboratory, lipid profile, treatment, and available genetic testing data from routine medical records without changing patient care. Participants are followed annually or more often if clinically indicated, and data are pseudonymized for analysis. The registry seeks to describe real-world diagnostic approaches, treatment patterns, and molecular-genetic characteristics to inform future research and improve patient care.
Why it matters
Potential benefit: If successful, the registry could help doctors better identify causes, personalize treatment, and reduce complications such as acute pancreatitis and cardiovascular events for people with extreme hypertriglyceridemia.
How similar studies have gone: Other national and international registries and genetic cohorts of severe hypertriglyceridemia have produced useful epidemiologic and genetic insights, although randomized interventional evidence remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol/L), confirmed by at least two independent measurements. * Written informed consent from the patient or legal guardian. * No age restrictions. Exclusion Criteria: * Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition. * Lack of informed consent.
Where it's running
-
Astrakhan State Medical University
Astrakhan, Russia Recruiting -
Chelyabinsk State Medical Academy
Chelyabinsk, Russia Recruiting -
Kaluga City Clinical Hospital No. 5
Kaluga, Russia Recruiting -
State Medical University
Kazan', Russia Recruiting -
National Medical Research Center of Cardiology Named after Academician E.I. Chazov
Moscow, Russia Recruiting -
Research Centre for Medical Genetics
Moscow, Russia Recruiting
Study contacts
- Principal investigator: Marat Ezhov — MD, PhD
- Study coordinator: Marat Ezhov, MD, PhD
- Email: Marat_Ezhov@mail.ru
- Phone: +7 495 414-6067
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ion775 for high triglyceride levels: safety, tolerability, and how well it works
A drug called ION775 is being tested to see if it can safely lower fasting triglycerides in adults with hypertriglyceridemia or severe hypertriglyceridemia who are already on standard lipid medicines.
-
CTX310 for refractory high triglycerides or LDL cholesterol
This trial will test whether a single IV dose of CTX310 is safe and tolerated in adults whose high triglycerides or LDL cholesterol have not responded to available treatments.
-
High-speed centrifugation to enable anti-Xa testing on lipemic (fatty) blood samples
This will test whether spinning fatty (lipemic) blood samples very fast helps the lab get accurate anti-Xa measurements for adults on anti-Xa anticoagulant medications.
-
MAR001 for adults with high triglycerides and remnant cholesterol
This trial will try the drug MAR001 to lower post-meal triglycerides and remnant cholesterol in adults with elevated triglyceride levels.
-
JMT202 injections for adults with high triglycerides
This will test whether repeated subcutaneous injections of JMT202 are safe and well tolerated in Chinese adults with high triglyceride levels.
-
MAR001 in adults with high triglycerides and remnant cholesterol
This study tests MAR001 against placebo to see if it lowers triglycerides and remnant cholesterol in adults with elevated levels.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.